Gilead Sciences (GILD) raises Revenue Guidance Following 3Q Beat; Maxim Group Reiterates Buy
Tweet Send to a Friend
Maxim Group reiterated a Buy rating on Gilead Sciences (NASDAQ: GILD), and raised the price target to $137.00 (from $129.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
